Beijing Whale Pharmatech Co.,Ltd
hereinafter referred to as: Whale Pharmatech
Whale Pharmatech was established in August 2020, primarily providing services for domestic and international innovative pharmaceutical companies, ranging from screening to customized synthesis of small molecule drugs.
We offer innovative process development and optimization services, including process research and development, as well as customized production services for pharmaceutical intermediates and active pharmaceutical ingredients. Our services cover small-scale production during the research and development phase to large-scale production during the commercialization phase. We aim to facilitate the practical technology transfer for research-oriented enterprises, reduce time to market for their products, and promote commercialization. Our goal is to help pharmaceutical companies save costs, mitigate risks, and enhance research and development efficiency.
Main Business
Whale Pharmatech focuses on the CDMO business of small molecule innovative drugs

Development of Characteristic Molecular Building Blocks
The company has developed a library of characteristic molecular building blocks to provide innovative pharmaceutical companies and other companies with raw materials for drug molecular building blocks and process development of new molecular building blocks. At present, it has matured production processes for various characteristic molecular building blocks including pyridines, indoles, and bromine-containing heterocycles.
Technical Advantages
The team consists of members who have graduated from renowned universities both domestically and internationally. They possess extensive experience in drug synthesis and production, particularly excelling in areas such as "asymmetric synthesis," "enzyme catalysis," and "microreactors." These technical advantages provide robust technical support for the entire process, from drug discovery to commercial production, ensuring the continuous iteration of superior drug varieties.
